81 related articles for article (PubMed ID: 23878055)
1. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.
Fetterly GJ; Aras U; Meholick PD; Takimoto C; Seetharam S; McIntosh T; de Bono JS; Sandhu SK; Tolcher A; Davis HM; Zhou H; Puchalski TA
J Clin Pharmacol; 2013 Oct; 53(10):1020-7. PubMed ID: 23878055
[TBL] [Abstract][Full Text] [Related]
2. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
Sandhu SK; Papadopoulos K; Fong PC; Patnaik A; Messiou C; Olmos D; Wang G; Tromp BJ; Puchalski TA; Balkwill F; Berns B; Seetharam S; de Bono JS; Tolcher AW
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1041-50. PubMed ID: 23385782
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
Pienta KJ; Machiels JP; Schrijvers D; Alekseev B; Shkolnik M; Crabb SJ; Li S; Seetharam S; Puchalski TA; Takimoto C; Elsayed Y; Dawkins F; de Bono JS
Invest New Drugs; 2013 Jun; 31(3):760-8. PubMed ID: 22907596
[TBL] [Abstract][Full Text] [Related]
4. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Brana I; Calles A; LoRusso PM; Yee LK; Puchalski TA; Seetharam S; Zhong B; de Boer CJ; Tabernero J; Calvo E
Target Oncol; 2015 Mar; 10(1):111-23. PubMed ID: 24928772
[TBL] [Abstract][Full Text] [Related]
5. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
Raghu G; Martinez FJ; Brown KK; Costabel U; Cottin V; Wells AU; Lancaster L; Gibson KF; Haddad T; Agarwal P; Mack M; Dasgupta B; Nnane IP; Flavin SK; Barnathan ES
Eur Respir J; 2015 Dec; 46(6):1740-50. PubMed ID: 26493793
[TBL] [Abstract][Full Text] [Related]
6. Dose selection of siltuximab for multicentric Castleman's disease.
Mayer CL; Xie L; Bandekar R; Qi M; van de Velde H; Reddy M; Qin X; Davis HM; Puchalski TA
Cancer Chemother Pharmacol; 2015 May; 75(5):1037-45. PubMed ID: 25784388
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty.
Mager DE; Mascelli MA; Kleiman NS; Fitzgerald DJ; Abernethy DR
J Pharmacol Exp Ther; 2003 Dec; 307(3):969-76. PubMed ID: 14534354
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
9. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888.
Obmolova G; Teplyakov A; Malia TJ; Grygiel TL; Sweet R; Snyder LA; Gilliland GL
Mol Immunol; 2012 Jun; 51(2):227-33. PubMed ID: 22487721
[TBL] [Abstract][Full Text] [Related]
11. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
Tan AR; Moore DF; Hidalgo M; Doroshow JH; Poplin EA; Goodin S; Mauro D; Rubin EH
Clin Cancer Res; 2006 Nov; 12(21):6517-22. PubMed ID: 17065274
[TBL] [Abstract][Full Text] [Related]
13. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects.
Bouman-Thio E; Franson K; Miller B; Getsy J; Cohen A; Bai SA; Yohrling J; Frederick B; Marciniak S; Jiao Q; Jang H; Davis H; Burggraaf J
J Clin Pharmacol; 2008 Oct; 48(10):1197-207. PubMed ID: 18812609
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma.
Puchalski T; Prabhakar U; Jiao Q; Berns B; Davis HM
Clin Cancer Res; 2010 Mar; 16(5):1652-61. PubMed ID: 20179212
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.
Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ
J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects.
Pérez-Ruixo JJ; Krzyzanski W; Bouman-Thio E; Miller B; Jang H; Bai SA; Zhou H; Yohrling J; Cohen A; Burggraaf J; Franson K; Davis HM
Clin Pharmacokinet; 2009; 48(9):601-13. PubMed ID: 19725594
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans.
Chow FS; Benincosa LJ; Sheth SB; Wilson D; Davis CB; Minthorn EA; Jusko WJ
Clin Pharmacol Ther; 2002 Apr; 71(4):235-45. PubMed ID: 11956506
[TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
